A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor
- 1 August 1996
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 74 (3) , 479-481
- https://doi.org/10.1038/bjc.1996.386
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.Journal of Clinical Oncology, 1995
- Paclitaxel (Taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines.1994
- The Role of the Reduced-Folate Carrier and Metabolism to Intracellular Polyglutamates for the Activity of ICI D1694Published by Springer Nature ,1993
- One-Sample Multiple Testing Procedure for Phase II Clinical TrialsPublished by JSTOR ,1982